Exosome‐Based Therapy: A Comparative Study of Adipose‐ and Umbilical Cord‐Derived Mesenchymal Stem Cells‐Derived Exosomes in Psoriatic Mouse Model

📖 Top 20% JournalNov 11, 2025Experimental dermatology

Exosome Therapy Using Fat- and Umbilical Cord–Based Stem Cells Compared in a Mouse Model of Psoriasis

AI simplified

Regenerative Health on OpenScience ↗PubMed ↗DOI ↗

Abstract

Both human adipose-derived and umbilical cord-derived MSCs' exosomes significantly reduced cumulative Psoriasis Severity Index scores by day 6 of treatment.

Exosomes from both human adipose-derived MSCs and human umbilical cord-derived MSCs significantly improved psoriasiform lesions.
Treatment with hUCMSCs-EXOs and desoximetasone (DSM) resulted in no significant epidermal and dermal thickness compared to control.
Immune cell infiltration was markedly reduced in groups treated with hUCMSCs-EXOs and DSM.
hUCMSCs-EXOs did not cause skin thinning or systemic side effects, unlike DSM.
hADMSCs-EXOs contained higher levels of certain growth factors, while hUCMSCs-EXOs had increased levels of HGF, important for immune regulation.

AI simplified

Exosomes are nanosized extracellular vesicles that mediate intercellular communication by transferring bioactive molecules. Mesenchymal stem cells (MSCs) from different tissue sources secrete exosomes with potentially distinct therapeutic properties. In this study, we compared the anti-inflammatory efficacy of exosomes derived from human adipose-derived MSCs (hADMSCs-EXOs) and human umbilical cord-derived MSCs (hUCMSCs-EXOs), together with desoximetasone (DSM), in an imiquimod-induced psoriasis mouse model. Psoriasiform lesions were induced, and treatment outcomes were assessed through clinical, histological, and immunological assessments. Both hADMSCs-EXOs and hUCMSCs-EXOs significantly attenuated psoriasiform lesions, as clinically evidenced by reduced cumulative Psoriasis Severity Index (PSI) scores by day 6 of treatment. Notably, hUCMSCs-EXOs and DSM significantly reduced epidermal and dermal thickness to no significant difference compared to the control group. Immune cell infiltration, including CD3, CD4, CD8T cells, CD68macrophages, CD117mast cells, and neutrophils, was also markedly reduced in the hUCMSCs-EXOs and DSM groups. Importantly, unlike DSM, hUCMSCs-EXOs did not induce skin thinning or systemic adverse effects. Growth factor (GF) profiling revealed that hADMSCs-EXOs were enriched in FGFs, PDGFs, and VEGF, whereas hUCMSCs-EXOs contained higher levels of HGF, a key modulator of immunoregulation and tissue repair. Collectively, these findings suggest that MSC-derived exosomes exert therapeutic effects through both anti-inflammatory and regenerative mechanisms, with hUCMSCs-EXOs demonstrating superior anti-inflammatory efficacy over hADMSCs-EXOs and a lower likelihood of inducing local or systemic adverse effects compared with DSM. Given the influence of MSC tissue origin on exosome content and function, our results support the potential of hUCMSCs-EXOs as a promising steroid-sparing therapeutic approach for psoriasis. + + + + +

Full Text

Full text is available at the source.

View full text ↗

Abstract

Full Text

Related papers